Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) has distinct origins: secondary (s-AML), therapy-related (t-AML), and de novo.
• The genetic underpinnings of these different AML pathways remain largely unknown.

Purpose of the Study:

• To investigate the genetic basis of s-AML and t-AML.
• To identify specific mutations associated with distinct AML subtypes and clinical outcomes.

Main Methods:

• Targeted mutational analysis was performed on 194 patients with s-AML or t-AML and 105 unselected AML patients.
• Mutations in specific genes (SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, STAG2) were analyzed.

Main Results:

• Mutations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 were >95% specific for s-AML diagnosis.
• These mutations were found to occur early in leukemogenesis and persist during remission.
• In t-AML and elderly de novo AML, these alterations defined a genetic subtype associated with worse outcomes, including lower complete remission rates and decreased event-free survival.

Conclusions:

• Specific gene mutations serve as highly specific biomarkers for secondary AML.
• These mutations identify a distinct genetic subtype in therapy-related and de novo AML, correlating with poorer clinical outcomes.
• Understanding these genetic alterations provides insights into AML pathogenesis and may inform therapeutic strategies.